It is made available under a CC-BY-NC-ND 4.0 International license .

Comprehensive Analysis of Therapeutic Strategies Using Mesenchymal Stem Cell-Derived 1 2 **Exosomes in Preclinical Models of Osteoarthritis** Riya Mukherjee¹, Ramendra Pati Pandey²⁺ Gunjan¹, Himanshu¹, Ing-Kae Wang³, Sing-Ying 3 Hsieh³, Chung-Ming Chang^{1,4,5*} 4 5 ¹Graduate of Institute **Biomedical** University: Sciences. Chang Gung 6 riya.mukherjee1896@gmail.com (R.M.). ²School of Health Sciences and Technology (SoHST), UPES Dehradun, Uttarakhand, India 7 8 ramendra.pandey@gmail.com (R.P.P.); ramendra.pandey@ddn.upes.ac.in 9 ³Cell Culture Medium Technology Development, Regeneration Medicine Technology Division, 10 Biomedical Technology and Device Research Laboratories, ITRI, Chutung, Hsinchu, Taiwan 310401, R.O.C. 11 ⁴Master 12 & Ph.D Program in Biotechnology Industry, Chang Gung University; cmchang@mail.cgu.edu.tw (C.M.C.). 13 14 ⁵Department of Medical Biotechnology Laboratory and Science; Chang Gung Universitycmchang@mail.cgu.edu.tw (C.M.C.). 15 16 17 ⁺⁺Contributed equally as first authorship ****Corresponding author** 18 19 20 Chung-Ming Chang*, Master & Ph.D. program in Biotechnology Industry, Chang Gung University, No.259, 21 Wenhua 1st Rd., Guishan Dist. Taoyuan City 33302, Taiwan (R.O.C.), cmchang@mail.cgu.edu.tw (C.M.C.). 22

23

24 Abstract

25 Background

Osteoarthritis (OA) is a common degenerative disease affecting people and animals, resulting in 26 27 persistent pain and joint deformities. Its growing prevalence presents considerable difficulties to public health and veterinary care systems worldwide. Despite substantial research, the molecular 28 pathways underlying OA pathogenesis remain poorly understood, limiting the development of 29 effective treatment strategies. Exosomes, or small endosomal membrane microvesicles, have 30 31 emerged as intriguing vehicles for intercellular communication and medicinal administration in a variety of illnesses, including OA. However, their efficacy and action methods in preclinical OA 32 models require additional exploration. 33

34 Methods

We analyzed several databases from 2016 to 2023 for original studies on exosome treatment in preclinical OA models. The inclusion criteria included studies that used exosomes generated

37 from mesenchymal stem cells (MSCs) in both human and animal models of OA. Thematic

- 38 synthesis and data extraction were used to examine research features, dosage administration
- techniques, and efficacy results. The quality of included studies was assessed using recognized

It is made available under a CC-BY-NC-ND 4.0 International license .

40 criteria, and statistical analysis was performed to determine the efficacy of exosome treatment in

- 41 decreasing Osteoarthritis Research Society International (OARSI) scores.
- 42

43 **Results**

Our study comprised thirteen peer-reviewed articles that included both human and animal models of OA. Most trials used bone marrow MSC-derived exosomes administered intraarticularly. The analysis of OARSI scores revealed a considerable reduction in joint deterioration following exosome therapy. Source analysis demonstrated that exosome treatment originating from human and animal MSCs was consistently effective. However, an assessment of study quality revealed potential biases and limitations, emphasizing the need for more research to validate these findings and refine therapy options for OA management.

51

52 Keywords

53 Osteoarthritis, Exosome Therapy, Mesenchymal Stem Cells, Preclinical Studies, Therapeutic

54 Efficacy.

55 Graphical Abstract



56 57

It is made available under a CC-BY-NC-ND 4.0 International license .

58 **1. Introduction**

59 Osteoarthritis (OA) is the most common degenerative disease both in humans and in animals, a leading cause of disability, and is characterized by chronic pain and a range of joint 60 abnormalities, including articular cartilage damage, synovial inflammation, subchondral bone 61 62 remodeling, and the formation of osteophytes (Steinmetz et al., 2023; Tong et al., 2022). The incidence of OA is steadily increasing due to the rising aging population and the global obesity 63 epidemic, imposing a significant socioeconomic burden and posing a significant challenge to 64 public health (A. R. Sun et al., 2021; Wen & Xiao, 2022; X. Wu et al., 2022). The World Health 65 66 Organization (WHO) has designated the period from 2021 to 2030 as the "Decade of Healthy Ageing," with a particular emphasis on enhancing both life expectancy and overall quality of 67 life. This designation presents an important opportunity to address the burden of OA within the 68 framework of adult health (WHO). Due to the chronic nature of osteoarthritis and its substantial 69 impact on mobility and daily functioning, this is especially important. According to a WHO 70 report, in 2019, approximately 528 million people worldwide were living with OA, marking a 71 113% increase since 1990. Most individuals affected by OA, about 73%, were aged 55 and older, 72 73 with females accounting for 60% of the total. With 365 million incidents, the knee emerged as the most affected joint, followed by the hip and the hand (WHO, 2023). A population-based 74 75 meta-analysis published in a Chinese publication in 2019 combined existing papers to determine the prevalence of knee joint osteoarthritis (OA) in China. The investigation found that the 76 77 prevalence of knee joint OA in China stood at 17%, with a breakdown of 12.3% in men and 22.2% in women (X. Sun et al., 2019). In a separate study conducted in 2019, which compiled 78 79 and analyzed existing publications, the research identified lumbar joint OA as the most widespread type of OA. It exhibited a prevalence rate of 25.03% in Chinese middle-aged and 80 elderly populations. Knee joint OA came in second with a prevalence of 21.51%, followed by 81 cervical joint OA at 20.46%, and hand joint OA at 8.99% (X. Sun et al., 2019). Additionally, in 82 83 Taiwan, knee OA has a prevalence rate of approximately 15%, impacting more than 3.5 million individuals who experience joint pain (DuoGenicStemCellscorporation, 2023). Furthermore, In 84 India, from 1990, OA, number rose from approximately 23.46 million people to 62.35 million by 85 2019 (Singh et al., 2022). According to the CDC, 32.5 million US individuals have OA, and 1 in 86 4 (or 54.4 million) US adults have some form of arthritis. By the year 2040, 78 million people 87 will be predicted to have arthritis worldwide (Alliance). In Western Europe, OA affected 88 89 approximately 57 million people in 2019 and cost over 2 million years of healthy life. Since 1990, the number of people affected in the area has increased by 54% (Economist, 2019). 90 Besides, in US, 63.4 million households have a dog, and there are an estimated 9 million pet 91 92 dogs owned there (PFMA, 2018), Osteoarthritis affects many dogs globally and is a danger to the 93 wellbeing of dogs. According to information gathered from 200 veterinarians, 20% of all dogs in North America over the age of one are estimated to have osteoarthritis (SA, 1997). Recent 94 95 estimates suggest that osteoarthritis affects 2.5% to 6.6% of dogs of all ages and breeds visiting 96 primary care offices in the United Kingdom (Pye et al., 2024). Canine osteoarthritis is a significant concern for veterinarians, owners, and breeders worldwide, and it has a considerable 97

It is made available under a CC-BY-NC-ND 4.0 International license .

impact on the welfare of dogs. The financial burden of treatment options for canine osteoarthritiscan be particularly challenging for dog owners.

At the molecular level, the pathogenesis of OA involves complex interactions between various 100 cellular and molecular processes. These include dysregulation of chondrocyte metabolism, 101 abnormal remodeling of the extracellular matrix, activation of inflammatory pathways, and 102 disruption of homeostatic mechanisms. Despite decades of research, the exact causes and 103 molecular mechanisms underlying OA are not fully understood, which contributes to the limited 104 effectiveness of traditional therapeutic approaches in stopping the progression of the disease 105 106 (Tong et al., n.d.). Chondrocytes, the cells responsible for maintaining cartilage integrity, play a central role in the pathogenesis of OA. Dysregulated chondrocyte metabolism leads to 107 imbalances in extracellular matrix (ECM) turnover, characterized by decreased synthesis of 108 collagen and proteoglycans, and increased expression of matrix metalloproteinases (MMPs) and 109 110 aggrecanases. These enzymes degrade the ECM, compromising cartilage structure and function. Synovial inflammation is a defining feature of osteoarthritis and contributes to its development. 111 OA joints exhibit higher levels of inflammatory mediators, including IL-1 β , TNF- α , and PGE2. 112 These cytokines enhance chondrocyte catabolism, accelerate cartilage breakdown, and drive 113 synovial cell production of inflammatory mediators. In OA, dysregulated signaling pathways 114 such NF-κB, MAPK, and Wnt/β-catenin contribute to inflammation, apoptosis, and ECM 115 degradation. The activation of these pathways results in the expression of pro-inflammatory 116 cytokines, catabolic enzymes, and cartilage breakdown mediators (Yao et al., n.d.). 117

118 Exosomes are small endosomal membrane microvesicles that have gotten a lot of interest in the 119 last decade. Exosomes were discovered in extracellular space as early as the late 1980s (Y. 120 Zhang, Liu, Liu, & Tang, 2019). Exosomes released by cells, on the other hand, were previously proposed as cellular waste resulting from cell injury or by-products of cell homeostasis, with no 121 122 substantial impact on nearby cells (Y. Zhang et al., 2019). It was only recently that these extracellular vesicles were shown to be functional vehicles capable of conveying a complex 123 cargo of proteins, lipids, and nucleic acids to the target cells they encountered, which may 124 eventually reprogram the destination cells distal from their release (S.-p. Li, Lin, Jiang, & Yu, 125 2018). Thus, exosomes constitute a novel route of intercellular communication that may be 126 127 important in a variety of cellular activities, including immunological response (Greening, Gopal, Xu, Simpson, & Chen, 2015), signal transduction (Gangoda, Boukouris, Liem, Kalra, & 128 Mathivanan, 2015), and antigen presentation (Smith, Cheng, Bryant, & Schorey, 2017). 129 Exosomes can be discharged by almost all eukaryotic cells, and their cargos are thought to differ 130 131 substantially depending on the origin of the cell type and its current condition (e.g. transformed, differentiated, stimulated, and stressed). Thus, exosomes and their biologically active cargos may 132 provide preemptive information in a variety of disorders, including neurodegenerative, and 133 degenerative diseases (Howitt & Hill, 2016; W. Liu et al., 2019). 134 Emerging studies demonstrated that, exosomes originating from mesenchymal stem cells (MSCs) provide 135 protective effects for bone and cartilage in OA (Zhu et al., 2017). They achieve this by elevating 136

It is made available under a CC-BY-NC-ND 4.0 International license .

137 the expression of chondrocyte markers such as type II collagen and aggrecan, suppressing

- 138 inflammatory markers like nitric oxide synthase (iNOS), preventing chondrocyte apoptosis, and
- promoting both the migration and proliferation of chondrocytes (Zhu et al., 2017) and inhibiting
- 140 the activation of macrophages (Cosenza, Ruiz, Toupet, Jorgensen, & Noël, 2017). Consequently,
- 141 exosomes are believed to have a role in the development and progression of various diseases,
- 142 including OA.

In the field of clinical practice, systematic reviews and meta-analyses, conducted with strict 143 adherence to scientific standards, are considered the most objective and comprehensive methods 144 145 for evaluating intervention effectiveness. To ensure the validity of our findings, we conducted a 146 thorough analysis of the efficacy and likely mechanisms of exosome utilization in both human and animal pre-clinical models of osteoarthritis. Our study focused uniquely on osteoarthritis 147 among the various degenerative diseases. We believe that this analysis of preclinical data will 148 149 significantly contribute to shaping the design of future clinical trials. The efficacy of exosomes in preclinical settings presents intriguing opportunities for future research in the veterinary and 150 public health fields. 151

152 **2. Materials and methods**

153 2.1. Data Collection

154 An extensive literature search was conducted from 2016 to 2023 by utilizing various databases, including Web of Science, Google Scholar, ScienceDirect, PubMed, ProQuest, EMBASE, and 155 SCOPUS. The aim was to carry out a comprehensive analysis focused on the topics of 156 157 'extracellular vesicles' or 'exosomes' and their relevance to 'osteoarthritis'. To construct our search strategy, we employed a combination of Medical Subject Headings (MeSH) terms, free-158 159 text keywords, and Boolean operators (AND or OR). The search strategy can be outlined as follows with the following keywords: (exosome OR microvesicles OR exosomes OR 160 161 extracellular vesicles) AND (human OR (animal OR mouse OR rat OR rabbit)) AND (arthritis or osteoarthritis OR degenerative joint disease OR Degenerative arthritis OR degenerative joint 162 disease OR Knee osteoarthritis). This search strategy was applied across different Medline 163 databases. The design and reporting of this study adhered to the guidelines outlined in the 164 165 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement 166 (Liberati, Altman, Tetzlaff, & Mulrow, 2009; A. Liberati et al., 2009).

167 *2.2. Inclusion and exclusion criteria*

Based on the specified inclusion and exclusion criteria below, a total of 13 papers were selected for retrieving information. Studies were included in the analysis if they met the following criteria: (i) original investigation in humans' and animals' pre-clinical models with osteoarthritis, (ii) exosome-based therapy, (iii) studies including author names, publication year, weight, number of dosages, dosage units, and route of administration. Articles undergoing full-text were

173 excluded for the following reasons: (i) being review articles, (ii) inability to extract or obtain data

It is made available under a CC-BY-NC-ND 4.0 International license .

from the original authors, (iii) incomplete data or data expressed as ratios or percentages, and (iv) not being published as a full-text article in a journal.

176 2.3. Data extraction

177 Data from various osteoarthritis (OA) treatments using exosomes were systematically compiled into a spreadsheet using Excel® (Microsoft® Office Excel 2013) and subjected to preliminary 178 testing before complete extraction. The extracted information included the author's name, 179 country of publication, year of publication (2017–2023), mesenchymal stem cell source, isolation 180 method, exosome size, tissue origin, exosome immunocompatibility, and associated degenerative 181 disease. Additionally, another spreadsheet was created to include author's name, dosage 182 administration, route of application, number of dosages, age, weight, and OARSI scores. The 183 collected data were analyzed further, and details related to OA treatment strategies were 184 meticulously organized into tables. Citations from the compiled papers were managed using 185 186 Endnote 20 (Clarivate Analytics, U.S.A).

187 2.4. Quality assessment

Assessment of the reporting quality of included studies was performed using a scoring system 188 189 adapted from (Papazova et al., 2015; Wever et al., 2012). Evaluating publication bias is essential to ensure the integrity and validity of our meta-analysis in assessing the effects of exosomes on 190 osteoarthritis (OA). Our approach aimed to systematically address any potential bias, ensuring 191 that our meta-analysis offers an impartial synthesis of the existing evidence on the therapeutic 192 benefits of exosomes in OA. Furthermore, we employed a risk bias checklist across multiple 193 194 domains (D1 to D5), with each domain evaluated using five categories: high risk, some concerns, low risk, no information, and not applicable. Evaluation of the risk of bias was performed using 195 version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2) (Sterne JAC, 2019). 196

197 2.5. Statistical analysis

The statistical analysis and generation of forest plots and heat maps for pooled summary 198 estimates were conducted using the meta or metaphor and stats package in R software. The 199 summary estimates were derived from pooled data of forest plots representing Osteoarthritis 200 201 Research Society International (OARSI) scores in the OA model of humans and animals before 202 and after exosome treatment. 95% confidence intervals (CI) and odds ratios (OR) for both fixedeffect and random-effects models were calculated. OARSI is a widely used indicator of success 203 in research on osteoarthritis. It was created by international specialists in the field working in 204 205 consensus, and it has been approved for use in clinical trials. Making use of a standardized outcome measure, such as the OARSI, can assist assure consistency between research and enable 206 useful comparisons. Utilizing OARSI can also make it easier to combine data from several 207 research, improving the meta-analysis's statistical power and accuracy. The I² and τ^2 statistics 208 were used to evaluate the heterogeneity of the data. Random-effect models were employed for all 209

It is made available under a CC-BY-NC-ND 4.0 International license .

210 meta-analyses, and the outcomes were presented in forest plots. Additionally, the statistical 211 significance was determined by p-value ($p \le 0.05$).

212 **3. Results**

213 *3.1. Study Selection*

A total of 1280 papers published between 2016 and 2023 were systematically categorized using 214 215 Medline databases i.e. PubMed, Google Scholar, Scopus, and ISI Web of Science. Following a preliminary assessment of titles and abstracts, 326 studies underwent initial screening. From 216 217 these, 247 records were excluded due to irrelevance or redundancy, leaving 79 articles for further examination. Subsequently, 59 articles were excluded for various reasons: 10 articles were 218 219 excluded for improper screening, 9 articles due to no relevant animal intervention, 32 articles 220 were review articles, 2 were case studies, 2 were book chapters, and 4 articles could not be accessed Further proper screening process include 20 studies. Among these, 7 articles were 221 excluded for the following reasons: in 5 articles, exosomes were not derived from mesenchymal 222 stem cells, and 2 articles had incomplete data. Finally, 13 studies (Cosenza et al., 2017; He et al., 223 224 2020; Jin et al., 2021; X. Li et al., 2021; Liang et al., 2022; Lin et al., 2021; Y. Liu et al., 2022; Tao et al., 2017; Wang et al., 2021; J. Wu et al., 2019; J. Zhang, Rong, Luo, & Cui, 2020; Zhu et 225 al., 2017). were selected for this meta-analysis. The study selection process adhered to the 226



It is made available under a CC-BY-NC-ND 4.0 International license .

227 PRISMA flow diagram (A. Liberati et al., 2009), depicted in Figure 1.

Figure 1. PRISMA chart depicting the inclusion criteria for studies investigating exosome therapy in preclinical models of osteoarthritis.

230 *3.2. Study Characteristics*

The study summarizes data from various studies on the use of exosomes derived from human 231 mesenchymal stem cells (MSCs) for osteoarthritis (OA) treatment, spanning from 2017 to 2022 232 (Table 1). Most studies are from China and focus on human-derived MSCs. A common aspect 233 234 among the studies is the use of ultracentrifugation as the primary method for exosome isolation, 235 seen in the works of Zhu et al. (2017), Lin et al. (2020), Jin et al. (2021), Liu et al. (2022), Wang et al. (2021), Tao et al. (2017), and Li et al. (2022). Other methods include tangential flow 236 filtration (Zhang et al., 2019) and the exoEasy Kit (Yang et al., 2022). The exosome sizes 237 238 reported range from 30 to 200 nm. The sources of MSCs vary, including induced pluripotent stem cells (ipMSC), synovial membrane MSCs (SMMSC), dental pulp stem cells (DpSCs), bone 239 marrow (BM), knee articular cartilage, human synovial tissue, embryonic stem cells, and 240 umbilical cord (UC) MSCs. 241

In terms of immunocompatibility, most exosomes are characterized as xenogenic, except for Liang et al. (2022), who reported allogenic exosomes. The studies uniformly target OA as the degenerative disease of interest. Despite variations in exosome sizes and specific MSC sources, the overarching goal remains the same: exploring the therapeutic potential of MSC-derived exosomes in OA treatment. The detailed scrutiny and organization of these studies into tables enable a comprehensive understanding of OA treatment strategies using exosomes, as well as the methodologies and outcomes associated with each study.

Publicatio	Author's	Countr	Size	Isolation	Source	Tissue	Exosome	Degenerative	Ref.
n Year	Name	У		Techniques	of	Origin	Immunoco	Disease	
					MSCs		mpatibility		
2017	Zhu. et.al	China	30-	Ultracentrifug	Human	ipMSC ¹ &	Xenogenic	OA	(Zhu et al.,
			150nm	ation		$SMMSC^2$			2017)
2020	Lin. et.al	China	134±2	Ultracentrifug	Human	DpSCs ³	Xenogenic	OA	(Lin et al.,
			9nm	ation					2021)
2021	Jin. et.al	China	50-	Ultracentrifug	Human	BM^4	Xenogenic	OA	(Jin et al.,
			150nm	ation					2021)

Table 1. Interventional data of exosomes derived from human sources.

Abbreviations

¹**ipMSC** : Induced pluripotent MSCs

² **SMMSC**: synovial membrane MSCs

³ **DpSCs:** Dental pulp stem cells

⁴ **BM:** Bone Marrow

It is made available under a CC-BY-NC-ND 4.0 International license .

2022	Liu. et.al	China	135.5n	Ultracentrifug	Human	HuSMC ⁵	Xenogenic	OA	(Y. Liu et
			m	ation					al., 2022)
2021	Wang.	China	100-	Ultracentrifug	Human	Knee articular	Xenogenic	OA	(Wang et
	et.al		120nm	ation		cartilage			al., 2021)
2017	Tao. et.al	China	30-	Ultracentrifug	Human	Human	Xenogenic	OA	(Tao et al.,
			150nm	ation		synovial			2017)
2019	Zhang.	Singapo	100-	Tangential	Human	Embryonic	Xenogenic	OA	(Zhang.
	et.al	re	200nm	Flow		stem cell			et.al, 2019)
				Filtration					
2022	Li.et.al	China	30-	Ultracentrifug	Human	UC^{6}	Not	OA	(Li.et.al,
			200nm	ation			specified		2022)
2022	Yang.	China	131.2n	exoEasy Kit	Human	BM	Not	OA	(Yang.
	et.al		m				specified		et.al, 2022)
2022	Liang.	China	150-	Centrifugatio	Human	BM	Allogenic	OA	(Liang et
	et.al		190nm	n					al., 2022)
								1	

250

251 Table 2, summarizes interventional data from studies on exosomes derived from animal sources for osteoarthritis (OA) treatment, spanning from 2017 to 2020 and involving researchers from 252 France and China. Common across these studies is the use of centrifugation for exosome 253 isolation, with Cosenza et al. (2017) and He et al. (2020) using standard centrifugation, and 254 Zhang et al. (2020) employing ultracentrifugation. The MSCs were sourced from rodents, 255 256 specifically mice (Cosenza et al., 2017) and rats (He et al., 2020; Zhang et al., 2020), with bone marrow (BM) being the primary tissue origin. Exosome sizes ranged from 96 nm to 153 nm, and 257 all exosomes were allogenic, indicating derivation from the same species but different genetic 258 backgrounds. Each study uniformly focused on OA, highlighting a shared interest in the 259 260 therapeutic potential of animal-derived MSC exosomes for this condition. The table's detailed 261 organization facilitates a comprehensive understanding of OA treatment strategies using these exosomes. 262

Table 2. Interventional data of exosomes derived from animal sources.

Publicatio	Author's	Countr	Size	Isolation	Source of	Tissue	Exosome	Degenerative	Ref
II I Cai	Ivallie	y	(IIII)	rechniques	MBCS	Oligin	ompatibil	Disease	
							ity		
2017	Cosenza.	France	96	Centrifugatio	Mouse	MBM ⁷	Allogenic	Osteoarthritis	(Cosenza et
	et.al			n					al., 2017)
2020	He. et.al	China	153	Centrifugatio	Rat	BM	Allogenic	Osteoarthritis	(He et al.,
				n					2020)

⁵ **HuSMC:** Human urine-derived stem cells

⁶ UC: Umbilical Cord

⁷ **MBM:** Murine Bone Marrow

It is made available under a CC-BY-NC-ND 4.0 International license .

2020	Zhang.	China	140	Ultracentrifug	Rat	BM	Allogenic	Osteoarthritis	(J. Zhang et
	et.al			ation					al., 2020)

264

265 *3.3. Dosage Administration*

266 The studies investigating the therapeutic efficacy of mesenchymal stem cell-derived exosomes in preclinical models of osteoarthritis (OA). Each study is characterized by specific parameters, 267 including dosage, administration route, number of dosages, age and weight of the animal models, 268 269 and the Osteoarthritis Research Society International (OARSI) scores before and after exosome treatment (Table 3). Notably, the studies emphasize the use of exosomes derived from human 270 sources, highlighting their potential therapeutic importance. Zhu et al. (2017) administered 8 µl 271 of human-derived exosomes at a concentration of $1.0 \square \times \square 10^{10}$ /ml via intra-articular injections, 272 with two doses given to 6-week-old animals. The primary outcome showed a significant 273 274 reduction in OARSI scores from 5 in the OA model to 1.75 after exosome treatment, indicating a 275 substantial therapeutic effect. Lin et al. (2021) employed a single intra-articular injection of 100 μ l human-derived exosomes in animals weighing approximately 358 ±5 grams, reporting a 276 primary outcome of a decrease in OARSI scores from 2.3 in the OA model to 1.25 post-277 278 treatment. Jin et al. (2021) used 50 μ l of human-derived exosomes at a concentration of 5 \times 10¹⁰/ml, administered via intra-articular injections, with two doses given to 8-week-old animals 279 weighing 200±20 grams. The primary outcome recorded a reduction in OARSI scores from 5.8 280 in the OA model to 2 after exosome treatment. Liu et al. (2022) applied two intra-articular 281 282 injections of 100 µl human-derived exosomes to 12-week-old animals weighing 250±20 grams. 283 This research demonstrated a primary outcome of a significant decrease in OARSI scores from 20.5 in the OA model to 11.5 after treatment. Wang et al. (2021) conducted their study using 30 284 ul human-derived exosomes administered intra-articularly in two doses, though the age and 285 weight of the animals were not specified. The OARSI scores were reduced from 21.2 in the OA 286 model to 10.5 following treatment. Lastly, Tao et al. (2017) administered 100 µl of human-287 derived exosomes via intra-articular injections in two doses to 12-week-old animals weighing 288 289 between 300-350 grams. This study observed a decrease in OARSI scores from 22 in the OA model to 9.25 after exosome treatment. 290

Author's Name	Dosage Administration		Administration Route	No. of dosage	Age (weeks)	Weight	OARSI Scores			Ref
	Control	Exosome Treatment		uosuge	((reens)		Control	OA Model	After Exosome Treatment	
Zhu. et.al	8 µl	(1.0□×□10^10/ml)	Intra-articular	2	6	NG	0.3	5	1.75	(Zhu et al., 2017)
Lin. et.al	100 µl	100 µl	Intra-articular	1	NG	358 ±5g	0.25	2.3	1.25	(Lin et al.,

Table 3. Dosage administration of human-derived exosome treatment for OA.

It is made available under a CC-BY-NC-ND 4.0 International license .

										2021)
Jin. et.al	50 µl	5 x 10^10/ml	Intra-articular	2	8	200±20g	4.3	5.8	2	(Jin et al., 2021)
Liu. et.al		100µ1	Intra-articular	2	12	250±20g	0.25	20.5	11.5	(Y. Liu et al., 2022)
Wang. et.al	30µl	30µ1	Intra-articular	2	NG	NG	0.25	21.2	10.5	(Wang et al., 2021)
Tao. et.al	100µ1	100µ1	Intra-articular	2	12	300- 350g	0.2	22	9.25	(Tao et al., 2017)

Comparatively, animal-derived exosomes also exhibited therapeutic efficacy but with varying 292 293 degrees of success (Table 4). For instance, Cosenza et al. (2017) observed a reduction in OARSI 294 scores from 11 to 5.8, and Liang et al. (2020) reported a decrease from 12.5 to 7.54. These 295 findings underscore the consistent and effective results of exosome treatments in reducing OA severity, with human-derived exosomes showing a slight edge due to more consistently effective 296 outcomes across multiple studies. This highlights the promising potential of both human and 297 298 animal-derived exosomes, emphasizing the need for further research to fully elucidate the 299 therapeutic mechanisms and optimize the clinical application of exosome-based therapies in OA 300 treatment.

Table 4. Dosage administration of animal-derived exosome treatment for OA.

Author's Name	Dosage units	Route of administration	No. of dosage	Age (weeks)	Weight		OARSI Sc	ores	Ref
						Control	OA Model	After Exosome Treatment	
Cosenza. et.al.	200ng	Intra-articular	3	10	NG	1.5	11	5.8	(Cosenza et al., 2017)
Zhang. et.al	40µl	Intra-articular	1	NG	200-250g	0.8	3.1	1.5	(He et al., 2020)
He. et.al	40µg	Intra-articular	1	10	NG	1	4.1	3	(Liang et al., 2022)
Liang. <i>et.al.</i>	50 or 100ug	Intra-articular	1	6	NG	0.3	12.5	7.54	(J. Zhang et al., 2020)

302

303 3.3. Analysis of Exosome Therapy Derived from Human and Animal Sources

It is made available under a CC-BY-NC-ND 4.0 International license .

The finding presents a comprehensive analysis of the overall efficacy of exosome treatments on osteoarthritis (OA) across all included studies. This forest plot **Figure 2**, aggregates data from both human and animal-derived exosomes, providing a pooled estimate that reflects the general effectiveness of these therapies in managing OA. The pooled estimate indicates a significant positive effect of exosome therapy, with an odds ratio (OR) of 0.51 (95% CI: 0.41 to 0.61), and a p-value of less than 0.01, demonstrating the therapy's effectiveness in reducing OA severity. However, substantial heterogeneity is observed among the studies ($I^2 = 94\%$), suggesting



311 considerable variability in effect sizes. In the studies for human-derived exosomes, Zhu et al. (2017) reported an OR of 0.34 (95% CI: 0.21 to 0.49), contributing 8.9% to the overall weight. 312 Tao et al. (2017) observed an OR of 0.52 (95% CI: 0.31 to 0.73), with a weight of 7.2%. Lin et 313 al. (2020) reported an OR of 0.50 (95% CI: 0.31 to 0.69), contributing 7.8% to the weight. Jin et 314 al. (2021) showed an OR of 0.50 (95% CI: 0.43 to 0.56), with a weight contribution of 10.2%. 315 Wang et al. (2021) observed an OR of 0.56 (95% CI: 0.49 to 0.63), contributing 10.2% to the 316 weight. Liu et al. (2022) reported an OR of 0.42 (95% CI: 0.35 to 0.49), with a weight 317 contribution of 10.2%. Li et al. (2022) showed the highest OR of 0.88 (95% CI: 0.80 to 0.93), 318 contributing 10.3% to the weight. Similarly, in the studies for animal-derived exosomes, Cosenza 319 320 et al. (2017) reported an OR of 0.38 (95% CI: 0.21 to 0.58), contributing 7.9% to the overall weight. He et al. (2020) showed an OR of 0.34 (95% CI: 0.22 to 0.48), with a weight 321 contribution of 9.1%. Zhang et al. (2019) reported an OR of 0.50 (95% CI: 0.41 to 0.59), 322 contributing 9.8% to the weight. Liang et al. (2022) observed an OR of 0.62 (95% CI: 0.46 to 323 324 0.77), contributing 8.5% to the weight.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2. The forest plot illustrates the efficacy rates of human and animal-derived exosomes *in vivo* treatment of OA (with their 95 % confidence intervals).

Both human and animal-derived exosomes demonstrate substantial reductions in OA severity,

with human-derived exosomes showing a broader range of ORs from 0.34 (Zhu et al., 2017) to

329 0.88 (Li et al., 2022), indicating variability but consistently effective outcomes. In contrast,

animal-derived exosomes show ORs ranging from 0.34 (He et al., 2020) to 0.62 (Liang et al.,

- 331 2022), also indicating efficacy but with slightly less variability. Human-derived exosome studies
- tend to have higher weight contributions (up to 10.3% for Li et al., 2022) compared to animal-
- derived exosome studies, suggesting a greater overall influence on the meta-analysis outcomes.
- This overview provides a crucial understanding of the broad impact of exosome-based therapies
- on OA, offering a snapshot of the therapeutic potential of these treatments across diverse study
- 336 conditions.

337

It is made available under a CC-BY-NC-ND 4.0 International license .

338 3.4. Assessment of Experimental Subjects and Osteoarthritis Models Utilized for Evaluating 339 Exosome Efficacy

A detailed assessment of experimental subjects and osteoarthritis (OA) models was utilized in 340 various studies to evaluate the efficacy of exosome therapy. Each study is represented by a bar 341 that indicates the OA model employed and the type of experimental subject used. The OA 342 models include Anterior Cruciate Ligament Transection (ACL) combined with Medial 343 Meniscectomy (MM), Anterior Cruciate Ligament Transection (ACLT) combined with 344 Destabilization of the Medial Meniscus (DMM), Collagenase-induced OA, DMM alone, Medial 345 346 Collateral Ligament (MCL) combined with MM, Monosodium Iodoacetate (MIA)-induced OA, 347 and Osteochondral Defect. The experimental subjects are color-coded to distinguish between Mice (C57BL/10), Mice (C57BL/6), New Zealand White Rabbits, and Rats (Sprague-Dawley). 348

- 349 The studies exhibit a diverse range of OA models and experimental subjects. For instance, Zhu et
- al. (2017) used C57BL/10 mice in an ACL & MM model, while Zhang et al. (2020) utilized
- 351 C57BL/6 mice in a DMM model. Zhang et al. (2019) and Yang et al. (2022) both employed New
- 352 Zealand White Rabbits but used different OA models, specifically ACLT & DMM and DMM,
- respectively. Studies by Wang et al. (2021) and He et al. (2020) used C57BL/6 mice in
- 354 Collagenase-induced and DMM models, respectively. The use of Sprague-Dawley rats is
- common in several studies, such as Tao et al. (2017), Liu et al. (2022), Lin et al. (2020), Liang et
- al. (2022), Li et al. (2022), Jin et al. (2021), and Cosenza et al. (2017). These studies employed a



variety of Figure 3. The heatmap illustrates the experimental subjects (on the right side) and
 osteoarthritis (OA) models (along the x-axis) analyzed across all studies (on the left side of the y axis).

It is made available under a CC-BY-NC-ND 4.0 International license .

OA models including MIA-induced, Osteochondral Defect, and combinations of ligament transection and meniscectomy. This diversity in experimental design reflects the different approaches to modeling OA and evaluating exosome efficacy, with each model and subject type providing unique insights into the therapeutic potential of exosomes.

Overall, this highlights the diversity in experimental methodologies used across studies assessing exosome therapy for OA. This underlines the importance of considering both the OA model and the experimental subject when interpreting results and comparing outcomes across different research efforts.

368 3.5. Source Analysis of Exosomes from Human and Animal Mesenchymal Stem Cells

The forest plot analysis shown in **Figure 4** provides a more detailed analysis by categorizing the studies based on the source of the exosome's human versus animal. This subgroup analysis offers a nuanced understanding of how the efficacy of exosome treatments varies depending on their origin. Many of the included publications, whether employing human or animal sources of mesenchymal stem cells, support exosome-based treatment for osteoarthritis. The analysis indicates that exosomes derived from human sources show a slightly higher pooled effect size of 0.53 [0.44; 0.63], compared to 0.44 [0.28; 0.60] for animal-derived exosomes, suggesting that



exosomes from human sources may have a marginally greater therapeutic impact on OA.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 4. The forest plot displays the efficacy of exosomes derived from human and animal mesenchymal stem cells, as reported in the selected studies.

379 Moreover, exosomes generated from bone marrow have been particularly noted for their 380 usefulness in the treatment of osteoarthritis, highlighting their potential not only in human applications but also for veterinary purposes. The heterogeneity within each subgroup ($I^2=94\%$) 381 for humans and $I^2=75\%$ for animals) emphasizes the variability in outcomes, with human-382 derived exosomes showing more inconsistency across studies. This detailed breakdown is 383 384 essential for clinicians and researchers who are considering the source of exosomes in their 385 therapeutic applications, as it provides insights into the relative efficacy and variability of human versus animal-derived treatments, with bone marrow-derived exosomes showing significant 386 387 promise.

388 *3.6. Risk of bias in the eligible studies*

Figure 5 provides a comprehensive risk of bias assessment for 13 included studies using the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies 2), evaluating five key domains: randomization process (D1), timing of participant recruitment relative to randomization (D1b), deviations from intended intervention (D2), missing outcome data (D3), outcome measurement (D4), and selection of reported results (D5). The majority of studies exhibit a low risk of bias across most domains, particularly in D2, D3, D4, and D5, indicating that these aspects were generally well-controlled. However, several studies (e.g., Wang et al., 2021; Tao et



It is made available under a CC-BY-NC-ND 4.0 International license .

396 al., 2017)

Figure 5. Grouped bar charts illustrating the risk of bias across 13 included studies, were assessed using the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies-2).

399 show a high risk of bias in D1, related to the randomization process, raising concerns about internal validity. The D1b domain was not applicable in many cases, reflecting its irrelevance to 400 some study designs. Moderate concerns are noted in a few studies (e.g., Jin et al., 2021) in 401 specific domains, and some studies lack sufficient information to assess certain biases fully, 402 403 particularly in D1b and D1. Overall, while most studies maintain low to moderate risks of bias, 404 significant issues in the randomization process in some studies highlight the need for rigorous study design and transparent reporting to ensure the reliability of findings in exosome-based 405 osteoarthritis treatments. 406

407 4. Discussion

In this study, we rigorously evaluated the efficacy of MSC-derived exosome therapy in mitigating osteoarthritis symptoms in preclinical animal models, while systematically elucidating the mechanisms underlying its therapeutic effects. Our focus on osteoarthritis is justified by its status as the most prevalent degenerative disease, a leading cause of disability, and its strong association with chronic pain and various joint abnormalities, including articular cartilage damage, synovial inflammation, subchondral bone remodeling, and osteophyte formation (Steinmetz et al., 2023; Tong et al., 2022).

415 We conducted a thorough analysis of 13 peer-reviewed studies published between 2016 and 2023, exploring the therapeutic potential of exosomes derived from both human and animal 416 sources. This analysis was designed to deepen our understanding of exosome therapy's impact on 417 osteoarthritis progression, accounting for critical factors such as administration methods, dosage 418 419 frequency, patient age, weight, and OARSI scores. Our findings unequivocally demonstrate 420 several key properties of exosomes, and the experimental models employed. Notably, exosomes, typically ranging in size from 30 to 150 nm, are most effectively administered via the intra-421 articular route. Despite the clear focus on human osteoarthritis in the literature, a glaring gap 422 423 persists in research on the application of exosome therapy in veterinary medicine. The reviewed studies consistently show that exosomes significantly reduce the inflammatory response and 424 improve OARSI scores, a crucial measure of osteoarthritis severity encompassing factors like 425 physical function, stiffness, and pain. Remarkably, none of the studies reported adverse effects, 426 underscoring the promise of exosome therapy, particularly as it results in significant reductions 427 428 in OARSI scores in preclinical settings.

Exosomes play an essential role in modulating immune responses, addressing cardiovascular disorders, combating degenerative diseases, and even influencing cancer progression. Their multifaceted functions, including tissue repair, immune response modulation, and inflammation reduction, position MSC-derived exosomes at the forefront of regenerative medicine (Zakirova et

It is made available under a CC-BY-NC-ND 4.0 International license .

al., 2020). Acting as intercellular messengers, exosomes transport biologically active
molecules—such as lipids, proteins, miRNAs, and multimolecular complexes—that are critical
in regulating homeostasis and metabolism (Colombo, Raposo, & Théry, 2014). These
characteristics make exosomes invaluable for both therapeutic and diagnostic applications, with
evidence suggesting that extracellular vesicles alone can effectively heal injuries and repair
tissue, thereby circumventing the practical challenges posed by stem cell-based protocols in
veterinary medicine (Diomaiuto et al., 2021).

The selection of appropriate animal models is indispensable in osteochondral defect and 440 441 osteoarthritis research. Our analysis identified the use of various animal models, including mice 442 (C57B/L10, C57B/L6), New Zealand White rabbits, and Sprague-Dawley rats, each offering unique advantages-whether in understanding genetic responses, anatomical similarities to 443 humans, or robustness and availability. The efficacy of exosome therapy for osteoarthritis is 444 evident, irrespective of the MSC source, with exosomes derived from human and animal sources, 445 particularly bone marrow, showing substantial promise in alleviating osteoarthritis symptoms. 446 The forest plot analysis further strengthens the case for exosome-based therapy, with the 447 majority of studies yielding positive results. 448

449 Our analysis highlights a critical limitation: the paucity of veterinary models in the existing literature. While research predominantly focuses on human osteoarthritis, there is a conspicuous 450 lack of studies investigating the use of exosomes in veterinary contexts. This gap limits the 451 generalizability of our findings to veterinary health, as the effectiveness of exosome therapy in 452 preclinical animal models may not fully capture the complexities of osteoarthritis in veterinary 453 454 patients. Additionally, the considerable variability in experimental methodologies, including delivery routes, dosage frequencies, and assessment techniques, introduces potential 455 inconsistencies and complicates the establishment of standardized protocols for exosome therapy 456 in both human and veterinary medicine. The transition from preclinical models to clinical 457 458 applications presents significant challenges, given the inherent differences between animal models and actual patients, whether human or veterinary, which may limit the direct applicability 459 of the findings. 460

461 Given these limitations, future research shifts must focus on exosome therapy in veterinary patients with osteoarthritis. Comparative studies involving a broader range of species—such as 462 dogs, cats, and horses—are essential to fully assess the efficacy and safety of exosome therapy 463 across diverse veterinary populations. Incorporating organ-on-chip (OOC) technology into these 464 investigations is a crucial next step. OOC platforms offer unparalleled insights into the 465 466 mechanisms and therapeutic benefits of exosome therapy by accurately replicating physiological 467 conditions, enabling real-time monitoring of cellular responses, and facilitating sophisticated disease modeling and high-throughput screening (Kang et al., 2021). This approach has the 468 potential to significantly enhance our understanding of exosome therapy's impact across different 469 470 species, thereby improving translational outcomes in veterinary medicine.

It is made available under a CC-BY-NC-ND 4.0 International license .

471 Furthermore, the standardization of experimental protocols—such as administration routes, dosage regimens, and outcome measures-is critical for enhancing the comparability and 472 reproducibility of research findings. Establishing consensus guidelines for conducting preclinical 473 exosome therapy studies will strengthen the robustness and credibility of the research, paving the 474 475 way for more reliable conclusions. As we move from preclinical research to clinical applications, well-designed clinical trials are essential to validate the safety and efficacy of exosome therapy 476 in osteoarthritis treatment for both human and veterinary patients. Such trials will provide 477 definitive evidence of the clinical utility of exosome therapy, laying the groundwork for its 478 broader adoption in medical practice. 479

480 **5. Conclusion**

In conclusion, our study unequivocally demonstrates the effectiveness of MSC-derived exosome 481 therapy in preclinical osteoarthritis models, underscoring the significant potential of exosome-482 483 based interventions to alleviate osteoarthritis symptoms. Through a rigorous and systematic analysis of existing literature, we have pinpointed critical factors that influence the success of 484 exosome therapy, including the source of mesenchymal stem cells, administration routes, and 485 experimental protocols. While our study acknowledges limitations, such as 486 the 487 underrepresentation of veterinary models and variability in experimental designs, these do not detract from the compelling evidence we present. Exosome therapy emerges as a promising and 488 innovative approach for treating osteoarthritis, poised to transform both human and veterinary 489 medicine. Moving forward, research efforts must intensify to resolve outstanding questions, 490 standardize protocols, and expedite the clinical application of exosome therapy. Our findings 491 492 contribute decisively to the growing body of evidence supporting the adoption of exosome therapy in osteoarthritis treatment, with far-reaching implications for both public and veterinary 493 health. 494

495

- 496 **Declaration of Interests:** The authors declare that they have no competing interests.
- 497 Ethics approval and consent to participate: 'Not applicable'
- 498 **Consent for publication**: All authors have given their consent to publish
- 499 Availability of data and materials: The authors confirm that the data supporting the findings of
- 500 this study are available within the article.
- 501 **Competing interests**: None
- 502 **Funding**: VtR Inc-CGU (SCRPD1L0221); DOXABIO-CGU (SCRPD1K0131), and CGU grant 503 (UZRPD1L0011, UZRPD1M0081).
- 504 **Authors' contributions**: All authors have equally contributed to the conceptualization, 505 methodology, and writing and editing of the manuscript.
- 506 Acknowledgements: This research was funded by VtR Inc-CGU (SCRPD1L0221); DOXABIO-
- 507 CGU (SCRPD1K0131), and CGU grant (UZRPD1L0011, UZRPD1M0081). We have not used 508 AI in the preparation of the manuscript.
- 509

510

It is made available under a CC-BY-NC-ND 4.0 International license .

5	1	1
5	т.	т.

- 512
- 513

550

- 514 **References**
- 515 Alliance, O. O. A. OA PREVALENCE AND BURDEN. Retrieved from 516 <u>https://oaaction.unc.edu/oa-module/oa-prevalence-and-burden/</u>
- Colombo, M., Raposo, G., & Théry, C. (2014). Biogenesis, secretion, and intercellular
 interactions of exosomes and other extracellular vesicles. *Annual review of cell and developmental biology*, 30, 255-289.
- Cosenza, S., Ruiz, M., Toupet, K., Jorgensen, C., & Noël, D. (2017). Mesenchymal stem cells
 derived exosomes and microparticles protect cartilage and bone from degradation in
 osteoarthritis. *Scientific Reports*, 7(1), 16214. doi:10.1038/s41598-017-15376-8
- Diomaiuto, E., Principe, V., De Luca, A., Laperuta, F., Alterisio, C., & Di Loria, A. (2021).
 Exosomes in Dogs and Cats: An Innovative Approach to Neoplastic and Non-Neoplastic
 Diseases. *Pharmaceuticals*, 14(8), 766. Retrieved from https://www.mdpi.com/1424-8247/14/8/766
- 527 DuoGenicStemCellscorporation. (2023). Treating Osteoarthritis Without Surgery! Bring you
 528 back to a lively life. Retrieved from <u>https://www.dgsc.com.tw/treat-osteoarthritis-</u>
 529 <u>without-surgery-freedom-of-movement-with-pcp-cell-</u>
 529 theremu(#) text. Osteoarthritis(% 20in% 20anb% 20
- 530therapy/#:~:text=Osteoarthritis%20is%20an%20arch%2Denemy,people%20suffer%20fr531om%20joint%20pain
- Economist, T. (2019) Spotlight on unmet needs in osteoarthritis; Global Burden of Disease Data
 Retrieved from
- 534https://osteoarthritisineurope.eiu.com/infographic/#:~:text=In%202019%2C%20over%2053557%20million,grown%20by%2054%25%20since%201990
- Gangoda, L., Boukouris, S., Liem, M., Kalra, H., & Mathivanan, S. (2015). Extracellular vesicles
 including exosomes are mediators of signal transduction: Are they protective or
 pathogenic? *PROTEOMICS*, *15*(2-3), 260-271.
 doi:https://doi.org/10.1002/pmic.201400234
- Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J., & Chen, W. (2015). Exosomes and their
 roles in immune regulation and cancer. *Seminars in Cell & Developmental Biology*, 40,
 72-81. doi:https://doi.org/10.1016/j.semcdb.2015.02.009
- He, L., He, T., Xing, J., Zhou, Q., Fan, L., Liu, C., . . . Rong, L. (2020). Bone marrow
 mesenchymal stem cell-derived exosomes protect cartilage damage and relieve knee
 osteoarthritis pain in a rat model of osteoarthritis. *Stem Cell Research & Therapy*, *11*(1),
 276. doi:10.1186/s13287-020-01781-w
- 547 Himanshu, Mukherjee R, Vidic J, Leal E, da Costa AC, Prudencio CR, Raj VS, Chang CM,
 548 Pandey RP. Nanobiotics and the One Health Approach: Boosting the Fight against
 549 Antimicrobial Resistance at the Nanoscale. Biomolecules. 2023 Jul 28;13(8):1182.

Howitt, J., & Hill, A. F. (2016). Exosomes in the Pathology of Neurodegenerative Diseases*.
 Journal of Biological Chemistry, 291(52), 26589-26597.
 doi:<u>https://doi.org/10.1074/jbc.R116.757955</u>

- Jin, Y., Xu, M., Zhu, H., Dong, C., Ji, J., Liu, Y., . . . Gu, Z. (2021). Therapeutic effects of bone marrow mesenchymal stem cells-derived exosomes on osteoarthritis. *Journal of Cellular and Molecular Medicine*, 25(19), 9281-9294. doi:<u>https://doi.org/10.1111/jcmm.16860</u>
- Kang, Y., Niu, Z., Hadlock, T., Purcell, E. K., Lo, T., Zeinali, M., Owen, S., Keshamouni, V. G.,
 Reddy, R. M., Ramnath, N., & Nagrath, S. (2021, January 28). On Chip Biogenesis of *Circulating NK Cell* Derived Exosomes in Non Small Cell Lung Cancer Exhibits
 Antitumoral Activity. Advanced Science. https://doi.org/10.1002/advs.202003747
- Li, S.-p., Lin, Z.-x., Jiang, X.-y., & Yu, X.-y. (2018). Exosomal cargo-loading and synthetic
 exosome-mimics as potential therapeutic tools. *Acta Pharmacologica Sinica*, 39(4), 542 551. doi:10.1038/aps.2017.178
- Li, X., Wang, Y., Cai, Z., Zhou, Q., Li, L., & Fu, P. (2021). Exosomes from human umbilical cord mesenchymal stem cells inhibit ROS production and cell apoptosis in human articular chondrocytes via the miR-100-5p/NOX4 axis. *Cell Biology International*, 45(10), 2096-2106. doi:https://doi.org/10.1002/cbin.11657
- Liang, Y., Xu, X., Xu, L., Iqbal, Z., Ouyang, K., Zhang, H., . . . Xia, J. (2022). Chondrocyte specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment.
 Theranostics, 12(11), 4866-4878. doi:10.7150/thno.69368
- Liberati, A., Altman, D., Tetzlaff, J., & Mulrow, C. (2009). G0tzsche PC, Ioannidis JP, et al. The
 PRISMA statement for reporting systematic reviews and meta-analyses of studies that
 evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*, 62(10),
 e1-34.
- Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., ... Moher,
 D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of
 studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*, 62(10), e1-34. doi:10.1016/j.jclinepi.2009.06.006
- Lin, T., Wu, N., Wang, L., Zhang, R., Pan, R., & Chen, Y.-F. (2021). Inhibition of chondrocyte apoptosis in a rat model of osteoarthritis by exosomes derived from miR 140 5p overexpressing human dental pulp stem cells. *Int J Mol Med*, 47(3), 7. doi:10.3892/ijmm.2020.4840
- Liu, W., Bai, X., Zhang, A., Huang, J., Xu, S., & Zhang, J. (2019). Role of Exosomes in Central
 Nervous System Diseases. *Frontiers in Molecular Neuroscience*, 12.
 doi:10.3389/fnmol.2019.00240
- Liu, Y., Zeng, Y., Si, H. B., Tang, L., Xie, H. Q., & Shen, B. (2022). Exosomes Derived From
 Human Urine-Derived Stem Cells Overexpressing miR-140-5p Alleviate Knee
 Osteoarthritis Through Downregulation of VEGFA in a Rat Model. *Am J Sports Med*,
 50(4), 1088-1105. doi:10.1177/03635465221073991
- Papazova, D. A., Oosterhuis, N. R., Gremmels, H., Van Koppen, A., Joles, J. A., & Verhaar, M.
 C. (2015). Cell-based therapies for experimental chronic kidney disease: a systematic
 review and meta-analysis. *Disease models & mechanisms*, 8(3), 281-293.
- Pandey RP, Mukherjee R, Chang CM. Emerging Concern with Imminent Therapeutic Strategies
 for Treating Resistance in Biofilm. Antibiotics (Basel). 2022 Apr 2;11(4):476.

595 596

Pandey RP, Mukherjee R, Priyadarshini A, Gupta A, Vibhuti A, Leal E, Sengupta U, Katoch
 VM, Sharma P, Moore CE, Raj VS, Lyu X. Potential of nanoparticles encapsulated drugs

for possible inhibition of the antimicrobial resistance development. Biomed
Pharmacother. 2021 Sep;141:111943.

- Pandey RP, Mukherjee R, Chang CM. Antimicrobial resistance surveillance system mapping in
 different countries. Drug Target Insights. 2022 Nov 30;16:36-48.
- 603 PFMA, P. P. (2018). APPA National Pet Owners Survey. Retrieved from 604 <u>https://www.pfma.org.uk/pet-population-2018</u>
- SA, J. (1997). Osteoarthritis. Joint anatomy, physiology, and pathobiology. *Vet Clin North Am Small Anim Pract.*, 27, 699–723. doi:10.1016/S0195-5616(97)50076-3
- Singh, A., Das, S., Chopra, A., Danda, D., Paul, B. J., March, L., . . . Antony, B. (2022). Burden of osteoarthritis in India and its states, 1990–2019: findings from the Global Burden of disease study 2019. Osteoarthritis and Cartilage, 30(8), 1070-1078. doi:https://doi.org/10.1016/j.joca.2022.05.004
- Sadhu S, Rizvi ZA, Pandey RP, Dalal R, Rathore DK, Kumar B, Pandey M, Kumar Y, Goel R,
 Maiti TK, Johri AK, Tiwari A, Pandey AK, Awasthi A. Gefitinib Results in Robust HostDirected Immunity Against *Salmonella* Infection Through Proteo-Metabolomic
 Reprogramming. Front Immunol. 2021 Mar 31;12:648710.
- Smith, V. L., Cheng, Y., Bryant, B. R., & Schorey, J. S. (2017). Exosomes function in antigen
 presentation during an in vivo Mycobacterium tuberculosis infection. *Scientific Reports*,
 7(1), 43578. doi:10.1038/srep43578
- Steinmetz, J. D., Culbreth, G. T., Haile, L. M., Rafferty, Q., Lo, J., Fukutaki, K. G., . . . Kopec, J.
 A. (2023). Global, regional, and national burden of osteoarthritis, 1990–2020 and
 projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet Rheumatology*, 5(9), e508-e522. doi:<u>https://doi.org/10.1016/S2665-9913(23)00163-7</u>
- Sterne JAC, S. J., Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett 623 MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, 624 Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart 625 LA, Tilling K, White IR, Whiting PF, Higgins JPT. (2019). RoB 2: a revised tool for 626 627 assessing risk of bias in randomised trials. BMJ (366), 14898. doi:https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool?authuser=0 628
- Sun, A. R., Udduttula, A., Li, J., Liu, Y., Ren, P.-G., & Zhang, P. (2021). Cartilage tissue
 engineering for obesity-induced osteoarthritis: Physiology, challenges, and future
 prospects. *Journal of Orthopaedic Translation*, 26, 3-15.
 doi:https://doi.org/10.1016/j.jot.2020.07.004
- Suresh K, Mahendra PS, Vijay kB, et al. Quality control of vaccines-A journey from classical
 approach to 3Rs. Microbiol Curr Res. 2018;2(2):14-30.
- Sun, X., Zhen, X., Hu, X., Li, Y., Gu, S., Gu, Y., & Dong, H. (2019). Osteoarthritis in the
 Middle-Aged and Elderly in China: Prevalence and Influencing Factors. *International Journal of Environmental Research and Public Health*, 16(23), 4701. Retrieved from
 https://www.mdpi.com/1660-4601/16/23/4701
- Tao, S.-C., Yuan, T., Zhang, Y.-L., Yin, W.-J., Guo, S.-C., & Zhang, C.-Q. (2017). Exosomes
 derived from miR-140-5p-overexpressing human synovial mesenchymal stem cells
 enhance cartilage tissue regeneration and prevent osteoarthritis of the knee in a rat model. *Theranostics*, 7(1), 180-195. doi:10.7150/thno.17133

- Tong, L., Yu, H., Huang, X., Shen, J., Xiao, G., Chen, L., . . . Chen, D. (2022). Current
 understanding of osteoarthritis pathogenesis and relevant new approaches. *Bone Research*, 10(1), 60. doi:10.1038/s41413-022-00226-9
- Wang, Z., Yan, K., Ge, G., Zhang, D., Bai, J., Guo, X., . . . Geng, D. (2021). Exosomes derived
 from miR-155-5p–overexpressing synovial mesenchymal stem cells prevent osteoarthritis
 via enhancing proliferation and migration, attenuating apoptosis, and modulating
 extracellular matrix secretion in chondrocytes. *Cell Biology and Toxicology*, *37*(1), 85doi:10.1007/s10565-020-09559-9
- Wen, C., & Xiao, G. (2022). Advances in osteoarthritis research in 2021 and beyond. *Journal of Orthopaedic Translation*, 32, A1-A2. doi:<u>https://doi.org/10.1016/j.jot.2022.02.011</u>
- Wever, K. E., Menting, T. P., Rovers, M., van der Vliet, J. A., Rongen, G. A., Masereeuw, R., . .
 Warlé, M. (2012). Ischemic preconditioning in the animal kidney, a systematic review and meta-analysis. *PloS one*, 7(2), e32296.
- 656 WHO. WHO's work on the UN Decade of Healthy Ageing (2021–2030). Retrieved from 657 https://www.who.int/initiatives/decade-of-healthy-ageing
- 658 WHO. (2023). Osteoarthritis. Retrieved from <u>https://www.who.int/news-room/fact-</u> 659 <u>sheets/detail/osteoarthritis</u>
- Wu, J., Kuang, L., Chen, C., Yang, J., Zeng, W.-N., Li, T., . . . Yang, L. (2019). miR-100-5pabundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage
 and ameliorate gait abnormalities via inhibition of mTOR in osteoarthritis. *Biomaterials*, 206, 87-100. doi:https://doi.org/10.1016/j.biomaterials.2019.03.022
- Wu, X., Lai, Y., Chen, S., Zhou, C., Tao, C., Fu, X., . . . Xiao, G. (2022). Kindlin-2 preserves
 integrity of the articular cartilage to protect against osteoarthritis. *Nature Aging*, 2(4),
 332-347. doi:10.1038/s43587-021-00165-w
- Yao, Q., Wu, X., Tao, C., Gong, W., Chen, M., Qu, M., Zhong, Y., He, T., Chen, S., & Xiao, G.
 (2023, February 3). Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-023-01330-w
- Zakirova, E. Y., Aimaletdinov, A. M., Malanyeva, A. G., Rutland, C. S., & Rizvanov, A. A.
 (2020). Extracellular Vesicles: New Perspectives of Regenerative and Reproductive
 Veterinary Medicine. *Frontiers in Veterinary Science*, 7. doi:10.3389/fvets.2020.594044
- Zhang, J., Rong, Y., Luo, C., & Cui, W. (2020). Bone marrow mesenchymal stem cell-derived
 exosomes prevent osteoarthritis by regulating synovial macrophage polarization. *Aging*(*Albany NY*), 12(24), 25138-25152. doi:10.18632/aging.104110
- Zhang, Y., Liu, Y., Liu, H., & Tang, W. H. (2019). Exosomes: biogenesis, biologic function and clinical potential. *Cell & Bioscience*, 9(1), 19. doi:10.1186/s13578-019-0282-2
- Zhu, Y., Wang, Y., Zhao, B., Niu, X., Hu, B., Li, Q., . . . Wang, Y. (2017). Comparison of
 exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and
 synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis. *Stem Cell Research & Therapy*, 8(1), 64. doi:10.1186/s13287-017-0510-9
- 683